A resident with dementia, anxiety disorder, and severe cognitive impairment received scheduled lorazepam 1 mg TID and was repeatedly observed asleep or difficult to arouse in her wheelchair, dining area, and common areas. The DON confirmed the medication was being used to prevent her from getting out of her wheelchair, and the care plan did not include non-pharmacological redirection measures for anxiety.
A resident with Alzheimer's disease and dementia was receiving risperidone 1 mg TID for dementia, but the record lacked documented indications for the antipsychotic, a physician review of continued need, and evidence that GDR was contraindicated. A psychotropic eval also noted no non-pharmacologic approaches were used before the medication, and although a psych consult was ordered, it was not completed.
Failure to Monitor Psychotropic Medication Effectiveness and Side Effects: The facility did not document monitoring for effectiveness, side effects, or adverse effects for three residents receiving psychotropic medications. A resident with depression and anxiety received paroxetine and buspirone, another resident with anxiety received hydroxyzine pamoate, and a third resident with dementia, Parkinson’s disease, depression, and anxiety received Zyprexa. Although care plans called for ongoing monitoring, the MAR/TAR, progress notes, and orders lacked documentation of the required assessments, and the DON confirmed the missing monitoring documentation.
A resident with major depressive disorder, anxiety disorder, and moderate cognitive impairment had a PRN Ativan order for anxiety with no stop date. Pharmacy noted the medication needed a stop date, but the order remained active beyond 14 days without documented rationale, and the DON confirmed the recommendation was not followed.
A resident received risperidone for dementia despite record review showing no hallucinations, delusions, or behavioral symptoms. The dose was increased, prior GDR attempts were noted, and the DON confirmed there was no signed consent and no documentation that the family had been educated on antipsychotic side effects.
Failure to Monitor Psychotropic Medications: Five residents receiving psychotropic meds, including antidepressants, antipsychotics, and anti-anxiety meds, had no documented monitoring for effectiveness or adverse reactions/side effects in the MAR, TAR, or clinical record. The residents had diagnoses such as dementia, Alzheimer’s disease, depression, anxiety, and insomnia, and the DON verified the lack of routine monitoring documentation. The care plans listed general monitoring interventions, but the records did not show where findings were documented.
Failure to Document Nonpharmacological Interventions Before PRN Ativan: A resident with respiratory failure, DM2, MDD, and CKD received PRN Ativan repeatedly over several months without documentation that nonpharmacological interventions were attempted first. The MAR showed multiple administrations, the MDS noted the resident was cognitively intact and taking antianxiety medication, and an ADON/LPN confirmed the lack of documentation for attempted nonpharmacological measures before the PRN psychotropic was given.
Psychotropic Medication Indications and Monitoring Not Properly Documented: Surveyors found that two residents had psychotropic medications ordered without appropriate documented indications, and two residents were not monitored for side effects. One resident with dementia, psychosis, and severe cognitive impairment had Seroquel and Depakote orders, but no adverse-effect monitoring was documented. Another resident with dementia, psychosis, depression, and CKD V had quetiapine orders, but side-effect monitoring was absent and AIMS testing was not completed per policy. A third resident with Alzheimer’s disease and dementia with agitation had olanzapine and risperidone orders with indications the DON confirmed were not appropriate.
A resident with dementia, epilepsy, chronic pain, anxiety, and depression was given Hydroxyzine for anxiety without documented non-pharmacological interventions or adequate indication. Staff observations showed the resident was generally pleasant, social, and easily redirected when emotional, and the only documented behavior issue was increased anxiety and crying. The DON stated the resident requested medication and that a room change was the intervention attempted, but the record showed the room change had been offered earlier and no other behavior incidents were documented.
A resident with Alzheimer's disease and severely impaired cognition was ordered Zyprexa and Risperdal for dementia-related use without an appropriate indication. The DON confirmed the meds were administered without a proper diagnosis, and online drug references showed both antipsychotics carry black box warnings and are not approved for dementia-related psychosis.
Self-audit
Pick a level of detail and, optionally, what to focus on — then generate a survey-ready checklist distilled from the most recent citations.
Beta · AI-generated — for reference only, not professional advice. Verify against current CMS guidance before relying on it. Assisto accepts no responsibility for how this checklist is used.
Citations used to create this checklist
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release October 8, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.